Table 1

Clinical and laboratory variables (mean (SEM)) of RA patients during treatment with infliximab

Weeks
02614
Where not specified differences between variables found at the time points of the study are not statistically significant.
*With respect to baseline (0); †with respect to second week.
Number of patients101088
Serum IL18 (pg/ml)1364 (384)739 (317)353 (165)196 (26.4)
p<0.005*p<0.01*p<0.01*
Serum IL12 (pg/ml)36.4 (26.4)41.2 (32)24.9 (19.1)
Serum IL13 (pg/ml)43.4 (12.2)50.9 (10.7)32.9 (11.8)
ESR (mm/1st h)46.2 (5.9)23.4 (2.6)36.2 (6.6)34 (7.9)
p<0.005*p<0.02†
CRP (mg/l)26.4 (6.4)8.7 (4.6)14.2 (4.2)17.6 (7.2)
p<0.02*p<0.03†
Number of tender joints31.5 (7.9)27.7 (8.3)19 (8)27.5 (9.9)
p<0.02*
Number of swollen joints10.4 (5.5)8.7 (4.7)4.5 (2.8)5.4 (3.4)
Patient's assessment of pain (cm)6.6 (0.8)5.7 (0.6)6 (0.8)6.1 (0.1)
Patient's global assessment of disease activity (cm)7.4 (0.7)6.2 (0.7)5.8 (0.8)6.8 (0.9)
p<0.02*
Physician's global assessment of disease activity (cm)6.2 (0.7)6 (0.8)5.2 (1)5.8 (1)
HAQ1.54 (0.21)1.51 (0.27)1.37 (0.3)1.53 (0.33)